A Multicenter, 3-Arm, Open-Label, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Tanibirumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors PharmAbcine
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 Jan 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 08 Jun 2016 Status changed from planning to not yet recruiting.